Editorial
Next generation macrolides for community-acquired pneumonia: will solithromycin rise to the occasion?
Abstract
Community-acquired pneumonia (CAP) remains the leading cause of death by an infectious disease (1). Although the aetiological agent varies by geographical location and population studied, in adults the most commonly isolated pathogens from adult CAP patients are bacteria.
